Clinical Trial Design Supports Original Accelerated Approval of Sunitinib for Gastrointestinal Stromal Tumors
American Association for Cancer Research (AACR)• Final phase III trial analyses substantiate interim results that led to FDA approval. • Crossover trial design worked and benefitted patients. • Long-term overall survival benefit estimated with no new adverse events.